Table 1 Demographic, clinical and laboratory parameters of patients who received IAJI in both treatment groups
TA | TH | P value | |
|---|---|---|---|
Number of patients | 51 | 51 | |
Number of joints, n(%) | 138 (47.3%) | 154 (52.7%) | 0.44 |
Female, n(%) | 37 (72.5%) | 38 (74.5%) | 0.50 |
Male, n(%) | 14 (27.5%) | 13 (25.5%) | |
Age at onset (yr) mean ± SD median | 4.39 ± 3.42 2.97 | 4.18 ± 3.16 3.01 | 0.76 |
Disease duration per joint, yr, mean (range) | 0.9 (0.086–6.84) | 1.14 (0.07–9.30) | 0.331 |
JIA subtype, n(%) | |||
Persistent oligoarticular | 42 (82.4%) | 43 (84.3%) | 0.85 |
Extended oligoarticular | 6 (11.8%) | 5 (9.8%) | |
RF negative polyarticular | 3 (5.9%) | 3 (5.9%) | |
Laboratory parameters at baseline: | |||
CRP (mg/dL) mean ± S.D. median | (±1.3) 0.8 | 1.3 (±1.2) 0.94 | 0.47 |
ESR (mm/hr) mean ± S.D. median | 29.8 (±17.3) 28.5 | 28.9 (±17.1) 24.5 | 0.83 |
ANA positive (> 1:40) | 26 (51%) | 31 (±60.8%) | 0.27 |
Type of joint injected, n(%) | |||
Knee | 85 (61.6%) | 95 (61.7%) | 0.45 |
Ankle | 33 (23.9%) | 40 (26%) | |
Wrist | 6 (4.3%) | 11 (7.1%) | |
Elbow | 11 (8%) | 7 (4.5%) | |
Other (fingers& toes etc.) | 3 (2.2%) | 1 (0.6%) | |
Number of joints first injected, n(%) | 98 (71%) | 100 (64.9%) | 0.162 |
Number of joints re-injected, n(%) | 40 (29%) | 54 (35.1%) | |
Systemic treatment (per injection), n(%) | |||
NSAID’s TX during injection | 106 (76.8%) | 125 (81.2%) | 0.220 |
NSAID’s after injection | 51 (37%) | 33 (21.4%) | 0.003* |
MTX during injection | 14 (10.1%) | 14 (9.1%) | 0.457 |
MTX after injection | 53 (38.4%) | 49 (31.8%) | 0.146 |
Anti TNFα during injection | 3 (2.2%) | 3 (1.9%) | 0.605 |
Anti TNFα after injection | 20 (14.5%) | 31 (20.1%) | 0.133 |